The designation for HCB101covers all forms of gastric cancer, including advanced gastric adenocarcinoma in both HER2-positive and HER2-negative patients
Duvakitug was well tolerated and safety was consistent with the induction study
Ind-Ra expects chronic therapies to outpace IPM as compliance improves and lifestyle diseases rise
If approved, Ameluz would become the first and only photodynamic therapy (PDT) photosensitizer for sBCC in the US
MYC, a master regulator of oncogenic transcription, drives multiple high-burden cancers but has long eluded direct pharmacologic control
The approval marks a major advance in targeted treatment for this rare, chronic autoimmune disease, offering twice-yearly maintenance dosing after two initial loading doses
Bocunebart works by blocking pituitary adenylate cyclase-activating polypeptide
PiNACLE is a head-to-head study comparing its next-generation CAR T-cell therapy against established therapies liso-cel and axi-cel in patients with relapsed or refractory large B-cell lymphoma
Subscribe To Our Newsletter & Stay Updated
